Lorna Rodriguez-Rodriguez

List of Publications by Year
in descending order

30 papers	2,864 citations	236925 25 h-index	454955 30 g-index
30 all docs	30 docs citations	30 times ranked	6435 citing authors

#	Article	IF	Citations
1	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 2013, 45, 371-384.	21.4	493
2	GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nature Genetics, 2013, 45, 362-370.	21.4	326
3	The CD44 Receptor Interacts with P-Glycoprotein to Promote Cell Migration and Invasion in Cancer. Cancer Research, 2005, 65, 6660-6667.	0.9	209
4	Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium. Endocrine-Related Cancer, 2013, 20, 251-262.	3.1	169
5	Molecular Characterization of Epithelial Ovarian Cancer: Implications for Diagnosis and Treatment. International Journal of Molecular Sciences, 2016, 17, 2113.	4.1	165
6	Targeted Nanomedicine for Suppression of CD44 and Simultaneous Cell Death Induction in Ovarian Cancer: An Optimal Delivery of siRNA and Anticancer Drug. Clinical Cancer Research, 2013, 19, 6193-6204.	7.0	149
7	Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies. International Journal of Epidemiology, 2013, 42, 579-589.	1.9	146
8	Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nature Communications, 2013, 4, 1628.	12.8	144
9	Nanotechnology approaches for personalized treatment of multidrug resistant cancers. Advanced Drug Delivery Reviews, 2013, 65, 1880-1895.	13.7	133
10	Identification of Function for CD44 Intracytoplasmic Domain (CD44-ICD). Journal of Biological Chemistry, 2012, 287, 18995-19007.	3.4	101
11	Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nature Communications, 2013, 4, 1627.	12.8	98
12	Racial/Ethnic Disparities in Ovarian Cancer Treatment and Survival. Clinical Cancer Research, 2016, 22, 5909-5914.	7.0	78
13	Phytoestrogen consumption from foods and supplements and epithelial ovarian cancer risk: a population-based case control study. BMC Women's Health, 2011, 11, 40.	2.0	71
14	Precision targeted therapy of ovarian cancer. Journal of Controlled Release, 2016, 243, 250-268.	9.9	59
15	Role of Biomarkers in the Development of PARP Inhibitors. Biomarkers in Cancer, 2016, 8s1, BIC.S36679.	3.6	57
16	Functional Polymorphisms in the TERT Promoter Are Associated with Risk of Serous Epithelial Ovarian and Breast Cancers. PLoS ONE, 2011, 6, e24987.	2.5	48
17	Multifunctional Tumor-Targeted Polymer-Peptide-Drug Delivery System for Treatment of Primary and Metastatic Cancers. Pharmaceutical Research, 2010, 27, 2296-2306.	3.5	47
18	Two-in-one: combined targeted chemo and gene therapy for tumor suppression and prevention of metastases. Nanomedicine, 2012, 7, 185-197.	3.3	43

#	Article	IF	Citations
19	Tumor-Targeted Responsive Nanoparticle-Based Systems for Magnetic Resonance Imaging and Therapy. Pharmaceutical Research, 2014, 31, 3487-3502.	3.5	43
20	CD44 promotes multi-drug resistance by protecting P-glycoprotein from FBXO21-mediated ubiquitination. Oncotarget, 2015, 6, 26308-26321.	1.8	42
21	Healthy eating index and ovarian cancer risk. Cancer Causes and Control, 2011, 22, 563-571.	1.8	39
22	CD44 in Ovarian Cancer Progression and Therapy Resistanceâ€"A Critical Role for STAT3. Frontiers in Oncology, 2020, 10, 589601.	2.8	39
23	Impact of Chemotherapy Dosing on Ovarian Cancer Survival According to Body Mass Index. JAMA Oncology, 2015, 1, 737.	7.1	38
24	Tumor Necrosis Factor-Î± Differentially Modulates CD44 Expression in Ovarian Cancer Cells. Molecular Cancer Research, 2006, 4, 511-520.	3.4	30
25	Emerging Role of Genomic Rearrangements in Breast Cancer: Applying Knowledge from Other Cancers. Biomarkers in Cancer, 2016, 8s1, BIC.S34417.	3.6	27
26	Phase I trial of selenium plus chemotherapy in gynecologic cancers. Gynecologic Oncology, 2018, 150, 478-486.	1.4	27
27	Impact of body mass index on ovarian cancer survival varies by stage. British Journal of Cancer, 2017, 117, 282-289.	6.4	25
28	Durable Response to PD1 Inhibitor Pembrolizumab in a Metastatic, Metaplastic Breast Cancer. Case Reports in Oncology, 2021, 14, 931-937.	0.7	8
29	Precision Medicine: Implications for Science and Practice. Journal of the American College of Surgeons, 2016, 223, 433-439e1.	0.5	6
30	Phase I trial of daily subcutaneous SPL-108 injections in combination with paclitaxel in patients with platinum resistant CD44+ advanced ovarian epithelial cancer. International Journal of Gynecological Cancer, 2022, 32, 1032-1038.	2.5	4